{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-024037","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2026-07-22T11:00:18+00:00","discovered_at":"2026-07-22T11:05:00.308175+00:00","generated_at":"2026-07-22T11:05:29.440429+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NRx Pharmaceuticals' subsidiary selected by DARPA for negotiation of potential award for SPARC-TMS trial","bullets":["NRX Defense Systems received DARPA letter selecting its proposal for negotiation of a potential award for SPARC-TMS phase 2/3 trial.","Trial combines robotic-enabled Transcranial Magnetic Stimulation with NRX-101 (D-cycloserine/lurasidone) for depression remission.","NRX-101 previously received FDA Breakthrough Therapy Designation; trial approved by FDA and posted on ClinicalTrials.gov (NCT07227103).","Study sites include Harvard McLean Hospital, HOPE Therapeutics clinics, and Walter Reed National Military Medical Center.","Selection does not constitute a final award; subject to successful negotiation of definitive terms with DARPA/DSO."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-024037","json":"https://secwatch.observer/filing/0001437749-26-024037.json","markdown":"https://secwatch.observer/filing/0001437749-26-024037.md","text":"https://secwatch.observer/filing/0001437749-26-024037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926024037/0001437749-26-024037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926024037/nrxp20260722_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T11:05:29.440429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}